Ozempic and Wegovy has been prescribed to Yorkshire patients hundreds of times in the past year - and it's not for weightloss ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

"The View" co-host Whoopi Goldberg addressed a "phony weight loss ad" circulating on Instagram during the show on Wednesday ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

More prescriptions were handed out for semaglutide – a drug used to treat diabetes – in Buckinghamshire last year, figures ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Tirzepatide, a GLP-1 medication already on the market to treat diabetes, is now FDA approved to help those suffering from ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...